2022

1. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

   European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46